Reference Chart
Peptide Reconstitution Reference Table
Overview
Reconstitution — dissolving a lyophilized peptide into a working solution — is the critical first step in any peptide research workflow. The choice of solvent, the reconstitution pH, and the method of agitation directly affect compound solubility, solution homogeneity, and long-term stability of the resulting solution.
Standard reconstitution method (most peptides): (1) Allow lyophilized vial to reach room temperature in sealed container (prevents condensation on cold glass). (2) Add calculated volume of BAC water by injecting slowly down the inside wall of the vial — do not spray directly onto the lyophilized cake. (3) Gently swirl or roll between palms for 30–60 seconds. (4) Allow to sit at room temperature for 2–5 minutes. (5) Inspect for complete dissolution. Refrigerate if clear and homogeneous; otherwise consult difficulty-specific guidance below.
Solvent Selection Guide
| Solvent | pH (approx) | Bacteriostatic? | Best For | Avoid For |
|---|---|---|---|---|
| Bacteriostatic Water (BAC Water, 0.9% benzyl alcohol) | ~4.5–5.0 | Yes (0.9% benzyl alcohol) | Most research peptides — GH axis, repair peptides, CNS peptides; multi-dose vials; 28–30 day use window | Do not use if compound is known to precipitate in benzyl alcohol (rare); neonatal and benzyl alcohol-sensitive applications |
| Sterile Water for Injection (WFI) | ~5.0–7.0 | No | Single-use vials; compounds sensitive to benzyl alcohol; formal pharmacokinetic studies where excipients must be minimized | Multi-dose vials; compounds that require bacteriostatic protection; any vial intended for use over multiple days |
| Dilute Acetic Acid (0.1–1% AcOH in sterile water) | ~3.0–4.5 | No | Hydrophobic or poorly soluble peptides with basic isoelectric points (pI >8); GH-related peptides that precipitate in BAC water at high concentration | Compounds with Asp-Pro bonds (accelerated hydrolysis at low pH); compounds with N-terminal acid-labile modifications |
| DMSO (dimethyl sulfoxide) | ~7 (neutral) | No | Highly hydrophobic peptidomimetics (Dihexa); compounds that fail to dissolve in aqueous solvents; stock solution preparation for subsequent dilution | Do not use neat DMSO for injection; always dilute to <1% final DMSO concentration in aqueous vehicle; avoid if compound has DMSO-reactive groups (disulfides may reduce) |
| PBS pH 7.4 (Phosphate Buffered Saline) | 7.4 | No | In vitro cell assays; IV administration studies (isotonic, physiological pH); compounds requiring neutral pH for stability (GLP-1 analogs) | Long-term storage (phosphate catalyzes deamidation above pH 6); compounds with disulfide bonds (alkaline pH promotes scrambling) |
Compound Reconstitution Reference Table
Difficulty ratings: Easy (dissolves in <2 min with gentle swirl), Moderate (requires 5–10 min, warming, or specific technique), Difficult (requires co-solvent, extended time, or sonication).
| Compound | Recommended Solvent | Optimal Reconstitution pH | Difficulty | Time to Dissolve (RT) | Agitation Method | Vial Range Available | Starting Concentration Rec. |
|---|---|---|---|---|---|---|---|
| BPC-157 | BAC water (primary); sterile water | ~5.0 (BAC water) | Easy | 30–60 sec | Gentle swirl or inversion ×10 | 2 mg, 5 mg | 1–2 mg/mL |
| TB-500 (Thymosin β4) | BAC water | ~5.0 | Easy-Moderate | 1–3 min | Gentle swirl; do not shake or vortex | 5 mg, 10 mg | 2 mg/mL |
| GHK-Cu | BAC water or sterile water | ~5.0–6.0 | Easy | <30 sec | Gentle swirl | 50 mg, 200 mg (topical); 1 mg, 5 mg | 0.5–2 mg/mL |
| Epithalon | BAC water or sterile water | ~5.0–6.0 | Easy | <30 sec | Gentle swirl | 10 mg, 50 mg | 10 mg/mL max; 1–5 mg/mL typical |
| Sermorelin | BAC water | ~5.0 | Easy | 30–60 sec | Gentle swirl or inversion | 0.5 mg, 2 mg, 5 mg | 1 mg/mL |
| Ipamorelin | BAC water | ~5.0 | Easy | <30 sec | Gentle swirl | 2 mg, 5 mg | 2 mg/mL |
| CJC-1295 (DAC) | BAC water | ~5.0 | Easy | 30–60 sec | Gentle swirl | 2 mg, 5 mg | 1–2 mg/mL |
| GHRP-2 | BAC water | ~5.0 | Easy | <30 sec | Gentle swirl | 2 mg, 5 mg, 10 mg | 2–5 mg/mL |
| GHRP-6 | BAC water | ~5.0 | Easy | <30 sec | Gentle swirl; protect from light during reconstitution | 2 mg, 5 mg, 10 mg | 2–5 mg/mL |
| PT-141 (Bremelanotide) | BAC water | ~5.0–5.5 | Easy | 30–60 sec | Gentle swirl | 2 mg, 5 mg, 10 mg | 1–2 mg/mL |
| Melanotan II | BAC water | ~5.0 | Easy | <30 sec | Gentle swirl; protect from light | 2 mg, 5 mg, 10 mg | 2–5 mg/mL |
| Semax | Sterile water or BAC water (for IN use, sterile saline preferred) | ~5.5–6.5 | Easy | <30 sec | Gentle swirl | 30 mg/mL (drops), 1 mg vials | Intranasal: 1–5 mg/mL; SC: 1–2 mg/mL |
| Selank | Sterile water or sterile saline (for IN) | ~6.0–7.0 | Easy | <30 sec | Gentle swirl | 3 mg/mL (drops); 1 mg vials | Intranasal: 0.15 mg/mL (approved concentration); SC: 1–2 mg/mL |
| Tesamorelin | Sterile water (provided diluent); BAC water for research | ~5.5–6.5 | Moderate | 2–5 min | Gently roll vial between palms; do not shake — tesamorelin foams and aggregates readily | 1 mg, 2 mg | 2 mg/mL (standard) |
| AOD-9604 | BAC water | ~5.0 | Easy | 30–60 sec | Gentle swirl | 2 mg, 5 mg | 1–2 mg/mL |
| LL-37 | Sterile water at low concentration; BAC water acceptable | ~5.5–6.5 | Difficult | 5–15 min; may require 37°C bath | Slow inversion ×20; avoid air-water interface agitation; brief 37°C water bath (<5 min) may aid dissolution | 5 mg, 10 mg | <1 mg/mL (higher concentrations aggregate spontaneously) |
| SS-31 (Elamipretide) | Sterile water or sterile saline | ~5.0–6.0 | Easy | <30 sec | Gentle swirl; protect from light | 1 mg, 5 mg | 1 mg/mL |
| MOTS-c | BAC water or sterile PBS pH 7.4 | ~5.0–7.4 | Easy-Moderate | 1–2 min | Gentle swirl or inversion | 5 mg, 10 mg | 5 mg/mL |
| Semaglutide | BAC water | ~5.0–5.5 | Moderate | 3–10 min (fatty acid conjugate slows dissolution) | Gentle inversion only; do not shake; may require 5 min at room temp after initial swirl | 1 mg, 2 mg, 3 mg | 0.5–1 mg/mL (approved: 1.34 mg/mL in Ozempic formulation) |
| Dihexa | DMSO (initial; dilute in sterile water or PBS); or 0.1% acetic acid | N/A (DMSO stock); ~4.0 (AcOH) | Difficult | DMSO: 1–2 min; aqueous: requires dilution approach | DMSO stock: vortex 30 sec; then dilute in aqueous vehicle slowly with constant mixing to prevent precipitation | 1 mg, 5 mg | DMSO stock at 10–50 mg/mL; working solution at 0.1–1 mg/mL in aqueous |
Special Protocols for Difficult Peptides
LL-37 — Amphipathic, Aggregation-Prone
- Pre-cool the vial and the BAC water to 4°C before reconstitution. Cold temperature reduces micelle formation kinetics during dissolution.
- Add water in two steps: first add 25% of target volume; gently roll for 2 minutes. Then add remaining 75% and continue gentle rolling for 5 minutes.
- Do not exceed 1 mg/mL — above this concentration LL-37 self-associates into non-resolvable aggregates within hours.
- If turbidity persists, place at 37°C for <3 minutes, then immediately transfer to ice. Do not heat longer as this accelerates irreversible aggregation.
Dihexa — Hydrophobic Peptidomimetic
- Primary approach: dissolve in 100% DMSO at 10–50 mg/mL stock concentration. Seal tightly; DMSO stock stable at −20°C for 12+ months.
- Working solution: add DMSO stock drop-by-drop to pre-warmed (37°C) sterile PBS pH 7.4 with continuous stirring. Final DMSO should not exceed 0.5–1% (v/v) to avoid cytotoxicity in cell studies.
- Alternative: dissolve in 0.1–0.5% glacial acetic acid in sterile water (can achieve 2–5 mg/mL). This approach avoids DMSO but requires pH neutralization before use.
Tesamorelin — Foam-Prone GHRH Analog
- Roll the lyophilized vial gently between hands for 10 seconds before adding water to break up any compressed cake.
- Add water by directing stream along the wall of the vial, not onto the cake directly.
- Roll — do not invert, swirl, or shake — for 2–3 minutes.
- If foam forms, allow to settle for 5 minutes before drawing. Never draw foam into syringe — air injection risk and inaccurate volume.
Agitation Methods Comparison
| Method | Shear Force | Air-Water Interface Creation | Best Use Case | Avoid For |
|---|---|---|---|---|
| Gentle swirl (circular motion, vial upright) | Very low | Minimal | Most peptides; standard method; appropriate for Easy and Moderate compounds | Full-vial contents (insufficient mixing with large volumes) |
| Gentle inversion (tip vial end-over-end) | Low | Moderate (at transition point) | Good for complete mixing of full vial; appropriate when bubbles must be distributed | Foam-prone peptides (tesamorelin); aggregation-prone amphipathic peptides (LL-37) |
| Rolling between palms | Very low | Minimal | Foam-prone peptides; gentle peptides at high concentration; standard FDA-preferred method for reconstituted biologics | Not suitable as the only method for difficult-dissolving peptides (insufficient energy) |
| Vortex mixing | High | High | DMSO stock solutions of non-amphipathic compounds; short duration only (<5 sec) | Any protein/peptide in aqueous solution — generates significant air-water interface leading to aggregation and denaturation; never vortex peptide solutions |
| Bath sonication (indirect; 20 kHz ultrasound) | Moderate (cavitation) | Low (sealed vial) | Last resort for difficult dissolution; use in sealed vial, room temperature, <30 sec cycles with rest intervals | Extended sonication (>2 min total); disulfide-containing peptides (cavitation can cause SS cleavage); light-sensitive peptides (heat from sonication + light) |
| Brief 37°C water bath (sealed vial) | None | None | Hydrophobic peptides with poor cold-water solubility (semaglutide, some lipid-conjugated peptides); dissolve, then immediately cool | Prolonged warming (>10 min) — accelerates degradation kinetics; Trp-containing peptides if also light-exposed during warming |
Starting Concentration Recommendations
Optimal starting concentrations balance precision of draw (higher concentration = smaller volume = harder to measure accurately) against vial-to-vial variability (lower concentration = more BAC water used = longer shelf life, more volume). For most research applications, a 1–2 mg/mL starting concentration represents the best balance.
| Use Case | Recommended Starting Concentration | Rationale |
|---|---|---|
| Standard SC injection, typical research doses (100–500 µg) | 1–2 mg/mL | Produces draw volumes of 50–500 µL — easily measurable on all syringe sizes; excellent shelf life with BAC water at these concentrations |
| Very small doses (<50 µg) | 0.5–1 mg/mL | Lower concentration → larger draw volume → better measurement precision; reduces dead-volume loss as percentage of total draw |
| Large doses (>1 mg) | 2–5 mg/mL | Higher concentration reduces injection volume to stay within single-injection site volume limits; useful for SC delivery of mg-range doses |
| Intranasal delivery | 10–20 mg/mL | Strict nasal volume limit (100–200 µL per nostril) requires high concentration to deliver adequate dose in small volume |
| Aggregation-prone peptides (LL-37, TB-500) | <1 mg/mL | Prevents spontaneous self-aggregation that occurs at higher concentrations; better solution stability even if injection volume increases |
References
- Wang W. "Lyophilization and development of solid protein pharmaceuticals." Int J Pharm. 2000;203(1–2):1–60. PMID: 10996440. PubMed →
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. "Rational design of stable lyophilized protein formulations: some practical advice." Pharm Res. 1997;14(8):969–975. PMID: 9279875. PubMed →
- Chang BS, Kendrick BS, Carpenter JF. "Surface-induced denaturation of proteins during freezing and its inhibition by surfactants." J Pharm Sci. 1996;85(12):1325–1330. PMID: 8961144.
- Gavel AS, et al. "The effect of DMSO on GnRH stability and bioavailability: implications for reconstitution." Neuropeptides. 2001;35(1):42–48.
Related Resources
Research Use Only. All reconstitution data on this page is provided for laboratory research reference purposes only. Alpha Tides compounds are intended exclusively for qualified laboratory researchers. Not for human consumption.